Generate Biomedicines: $1.2B valuation, IPO Readiness 56, Series A. Generate Biomedicines uses AI diffusion models and large-scale protein language models to generate novel thera. Track live on The IPO Stack.
Generate Biomedicines uses AI diffusion models and large-scale protein language models to generate novel therapeutic proteins and entire molecules from scratch — designing drugs that have never existed before in weeks instead of years. Valued at $1.2B with $400M raised from Andreessen Horowitz, Generate Biomedicines has multiple preclinical programs in oncology and immunology. Major AI biotech IPO candidate as AI-driven protein generation transforms pharmaceutical R&D from a trial-and-error process into a computational engineering discipline.
Scores, valuations, and IPO signals for the companies that matter. 5-minute read, every Tuesday.
Top companies most likely to IPO in 2026, ranked by IPO Readiness Score.
Track Generate Biomedicines IPO timeline, funding rounds, investor activity, and valuation on TechStackIPO — the pre-IPO intelligence platform.
Generate Biomedicines has not publicly announced IPO plans. Track TechStackIPO for the latest signals and subscribe to The IPO Stack for weekly updates.
Generate Biomedicines is valued at $1.2B as of December 2021. This valuation is based on its most recent private funding round tracked by TechStackIPO.
Accredited investors can access Generate Biomedicines shares through secondary market platforms, pre-IPO investment funds, and broker-dealer platforms that facilitate private company transactions. TechStackIPO's marketplace tracks available access options. Note: pre-IPO investments carry higher risk and limited liquidity compared to public market investing.
Generate Biomedicines scores 56/100 (Grade: C) on TechStackIPO's IPO Readiness Index. The score evaluates funding scale, valuation trajectory, funding momentum, stage progression, and company maturity. Scores above 70 indicate strong near-term IPO potential.
Generate Biomedicines has raised $150M in total venture capital and private equity funding, with backing from ARCH Venture Partners, Foresite Capital, T. Rowe Price.
Generate Biomedicines's notable investors include ARCH Venture Partners, Foresite Capital, T. Rowe Price. Full investor details, funding round history, and lead investor breakdowns are available on TechStackIPO.
Generate Biomedicines is a Biotechnology company. Generate Biomedicines uses AI diffusion models and large-scale protein language models to generate novel therapeutic pro.